[
  {
    "ts": null,
    "headline": "FDA APPROVES TEZSPIRE速 FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS",
    "summary": "Amgen (NASDAQ:AMGN) and AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) approved TEZSPIRE速 (tezepelumab-ekko) for the add-on maintenance treatment of inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) in adult and pediatric patients aged 12 years and older. TEZSPIRE is the first and only biologic approved for CRSwNP that targets thymic stromal lymphopoietin (TSLP).",
    "url": "https://finnhub.io/api/news?id=6741d71c1dd3a5cc3ffc6db0ed3e4221be51940bb03e1780cccf0a1330e3d2be",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760731200,
      "headline": "FDA APPROVES TEZSPIRE速 FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS",
      "id": 137162871,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (NASDAQ:AMGN) and AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) approved TEZSPIRE速 (tezepelumab-ekko) for the add-on maintenance treatment of inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) in adult and pediatric patients aged 12 years and older. TEZSPIRE is the first and only biologic approved for CRSwNP that targets thymic stromal lymphopoietin (TSLP).",
      "url": "https://finnhub.io/api/news?id=6741d71c1dd3a5cc3ffc6db0ed3e4221be51940bb03e1780cccf0a1330e3d2be"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Inc. stock outperforms competitors on strong trading day",
    "summary": "Amgen Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=03931316f0db0693b2644ddf93797d4d197cdc3ede21b5979cacb3e7aec18437",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760718900,
      "headline": "Amgen Inc. stock outperforms competitors on strong trading day",
      "id": 137138767,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "Amgen Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=03931316f0db0693b2644ddf93797d4d197cdc3ede21b5979cacb3e7aec18437"
    }
  },
  {
    "ts": null,
    "headline": "FDA Approves Amgen and AstraZeneca Treatment for Nasal Polyps Condition",
    "summary": "FDA Approves Amgen and AstraZeneca Treatment for Nasal Polyps Condition",
    "url": "https://finnhub.io/api/news?id=839ab6f7c76160f8e7b5e4080934a8d4869093a260c601ef616d23ebcedb2b2a",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760718600,
      "headline": "FDA Approves Amgen and AstraZeneca Treatment for Nasal Polyps Condition",
      "id": 137138768,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "FDA Approves Amgen and AstraZeneca Treatment for Nasal Polyps Condition",
      "url": "https://finnhub.io/api/news?id=839ab6f7c76160f8e7b5e4080934a8d4869093a260c601ef616d23ebcedb2b2a"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights Eli Lilly, Novo Nordisk, Amgen and Viking Therapeutics",
    "summary": "Eli Lilly's blockbuster GLP-1 drugs, Mounjaro and Zepbound, are driving explosive growth as the company prepares to report Q3 results.",
    "url": "https://finnhub.io/api/news?id=85c65f5784f3f16a210fe2ddcd312f564b27436e83907158d1cef050de7fdd15",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760696520,
      "headline": "The Zacks Analyst Blog Highlights Eli Lilly, Novo Nordisk, Amgen and Viking Therapeutics",
      "id": 137125649,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Eli Lilly's blockbuster GLP-1 drugs, Mounjaro and Zepbound, are driving explosive growth as the company prepares to report Q3 results.",
      "url": "https://finnhub.io/api/news?id=85c65f5784f3f16a210fe2ddcd312f564b27436e83907158d1cef050de7fdd15"
    }
  },
  {
    "ts": null,
    "headline": "Cullinan Therapeutics: Worthy Of A Small Position",
    "summary": "Cullinan Therapeutics trades near cash after a major drop, with pipeline risks but upside from CLN-978 and Zipalertinib trials. Read why CGEM stock is a buy.",
    "url": "https://finnhub.io/api/news?id=0ff6cf42130fc3fc9b40c647542d94b513a53386dd0544efb978c5a6013c93ce",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760684507,
      "headline": "Cullinan Therapeutics: Worthy Of A Small Position",
      "id": 137124660,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1295160689/image_1295160689.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Cullinan Therapeutics trades near cash after a major drop, with pipeline risks but upside from CLN-978 and Zipalertinib trials. Read why CGEM stock is a buy.",
      "url": "https://finnhub.io/api/news?id=0ff6cf42130fc3fc9b40c647542d94b513a53386dd0544efb978c5a6013c93ce"
    }
  }
]